Developing immunotherapies with Hu-NSG-MHC I/II DKO mice

30 May 2022

The NSG-MHC I/II DKO mouse model has the features of the severe combined immune deficiency mutation (scid), IL2 receptor gamma chain deficiency, MHC class I molecule deficiency (H2-K and D), and MHC class II molecule deficiency (IA). Due to the deficiency of murine MHC class I and class II molecules, this model demonstrates significantly delayed onset of graft-versus-host disease (GvHD) when transplanted with pre-characterized human PBMCs.

In this video, The Jackson Laboratory discusses using PBMC humanized NSG-MHC I/II DKO mice in preclinical research to develop and assess efficacy of human immuno-therapeutics.